Applying patient selection criteria for drotrecogin alfa therapy in practice

American Journal of Health-System Pharmacy

Volumn 60, Issue 13, 2003, Pages 1345-1352

  Wong Beringer, Annie ^a,b   Liao, Cindy ^a,c   Nguyen, Megan ^d   Pallares, Jean ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d Bioanalysis Research Group   (Egypt)

^e HMH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFECTIVE AGENT; CYTOKINE; DROTRECOGIN; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; PROTEIN C; RECOMBINANT PROTEIN;

APACHE; CLINICAL TRIAL; DRUG COST; FLUID THERAPY; HOSPITAL CARE; HOSPITAL COST; HUMAN; INCIDENCE; MACROPHAGE; MEDICAL PRACTICE; MORTALITY; NEUTROPHIL; NOTE; PATIENT SELECTION; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; TREATMENT PLANNING; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; HOSPITAL BED CAPACITY; LENGTH OF STAY; MALE; MIDDLE AGED; PRACTICE GUIDELINE;

AGED; ANTI-INFECTIVE AGENTS; APACHE; FEMALE; GUIDELINE ADHERENCE; HOSPITAL BED CAPACITY, 500 AND OVER; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 0242368080     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.13.1345     Document Type: Note

References (10)

1. Angus DC, Linde-Awirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303-10.
2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999; 340:207-14.
3. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992; 101:1644-55.
4. Kanji S, Devlin JW, Piekos KA et al. Recombinant human activated protein C, drotrecogin alfa activated: a novel therapy for severe sepsis. Pharmacotherapy. 2001; 21:1389-402.
5. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med. 2001; 29(suppl):S53-61.
6. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis (PROWESS trial). N Engl J Med. 2001; 344:699-709.
7. Manns BJ, Lee H, Doig CJ et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002; 347:993-1000.
8. Food and Drug Administration Anti-infective Drugs Advisory Committee. Drotrecogin alfa briefing information. www.fda.gov/orhms/dockets/ac/01/briefing/ 3797b1.htm (accessed 2001 Oct 16).
9. Warren HS, Suffredini AF, Eichacker PQ et al. Sounding board: risks and benefits of activated protein C in the treatment for severe sepsis. N Engl J Med. 2002; 347:1027-30.
10. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13:818-29.